A leptin–adiponectin ratio assessment in cancer was conducted by Słomian et al. A study with 43 ovarian cancer patients presented no relationship between the disease severity with the response to treatment and the concentration of the adipokines, although the leptin–adiponectin ratio before treatment correlated with a better response to chemotherapy, i.e., the lower the ratio, the better the clinical response, which leads us to consider the leptin–adiponectin ratio as a predictor of clinical response to treatment [126]. The gene discussed is ADIPOQ; the disease is ovarian cancer.